NEW YORK--(BUSINESS WIRE)--Antigenics Inc. (NASDAQ: AGEN) reported results today for the quarter ended September 30, 2006. The company incurred a net loss attributable to common stockholders of $11.2 million, or $0.24 per share, basic and diluted, for the third quarter of 2006, compared with a net loss attributable to common stockholders in the third quarter of 2005 of $17.5 million, or $0.38 per share, basic and diluted. The decreased loss reflects, among other factors, the company’s ongoing commitment to reducing cash burn.
